Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease

Scandinavian Cardiovascular Journal

Volumn 41, Issue 3, 2007, Pages 138-141

  Poussa, Heikki ^a   Strandberg, Timo E ^b   Tikkanen, Ilkka ^a   Kauhanen, Petteri ^a   Lepäntalo, Mauri ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Cholesterol; Dyslipidemia; Peripheral artery disease; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOGRAPHY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; DYSLIPIDEMIA; ENDOVASCULAR SURGERY; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FINLAND; GUIDELINE ADHERENCE; HOSPITALS, UNIVERSITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TRIGLYCERIDES;

EID: 34248992879     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430601187751     Document Type: Article

References (24)

1. Golomb, BA, Dang, TT and Criqui, MH. (2006) Peripheral arterial disease. Morbidity and mortality implications. Circulation., 114, pp. 688-699.
2. Aronow, WS and Ahn, C. (1994) Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women >62 years of age. Am J Cardiol., 74, pp. 64-65.
3. Ness, J. and Aronow, WS. (1999) Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc., 47, pp. 1255-1256.
4. Hackam, DG. (2005) Cardiovascular risk prevention in peripheral artery disease. J Vasc Surg., 41, pp. 1070-1073.
5. Eberhardt, RT and Coffman, JD. (2004) Cardiovascular morbidity and mortality in peripheral arterial disease. Curr Drug Targets Cardiovasc Haematol Disord., 4, pp. 209-217.
6. Criqui, MH, Langer, RD, Fronek, A., Feigelson, HS, Klauber, MR and McCann, TJ (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med., 326, pp. 381-386.
7. Youssef, F., Gupta, P., Mikhailidis, DP and Hamilton, G. (2005) Risk modification in patients with peripheral arterial disease: A retrospective survey. Angiology., 56, pp. 279-287.
8. Durazzo, AES, Machado, FS, Ikeoka, DT, De Bernoche, C., Monachini, MC and Puech-Leao, P. (2004) Reduction in cardiovascular events after vascular surgery with atorvastatin. A randomized trial. J Vasc Surg., 39, pp. 967-975.
9. Poldermans, D., Bax, JJ, Kertai, MD, Krenning, B., Westerhout, CM and Schinkel, AFL (2003) Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation., 107, pp. 1848-1851.
10. Ward, R Parker, Leeper, NJ, Kirkpatrick, JN, Lang, RM, Sorrentino, MJ and Williams, KA. (2005) The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol., 10, pp. 264-268.
11. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised plasebo-controlled trial. Lancet, 360, pp. 7-22.
12. Pedersen, TR, Kjekshus, J. and Pyörälä, K. (1998) Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol., 81, pp. 333-335.
13. Aronow, WS and Ahn, C. (2002) Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol., 90, pp. 789-791.
14. Aronow, WS, Nayak, D., Woodworth, S. and Ahn, C. (2003) Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and at 1 year after treatment. Am J Cardiol., 92, pp. 711-712.
15. Mohler, ER, Hiatt, WR and Creager, MA. (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation., 108, pp. 1481-1486.
16. Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T. and Agricola, E. (2003) Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med., 114, pp. 359-364.
17. De Backer, G., Abrosioni, E., Borch-Johnsen, K., Brotons, C., Cifkova, R. and Dallongeville, J. (2003) European Guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J., 24, pp. 1601-1610.
18. Cote, MC, Ligeti, R., Cutler, BS and Nelson, PR. (2003) Management of hyperlipidemia in patients with vascular disease. J Vasc Nurs., 21, pp. 63-67.
19. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet, 366, pp. 1267-1278.
20. Pearson, TA, Laurora, I., Chu, H. and Kofenk, S. (2000) The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med., 160, pp. 459-467.
21. Krobot, KJ, Yin, DD, Alemao, E. and Steinhagen-Thiessen, E. (2005) Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: Relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil., 12, pp. 37-45.
22. Grundy, SM, Cleeman, JI, Merz, CN Bairey, Brewer, HB, Clark, LT and Hunninghake, DB (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol., 44, pp. 720-732.
23. Strandberg, T. and Vanhanen, H. (2006) Reaching the goals for the treatment of dyslipidemia in 2000 and 2005: Has there been any progress? (English summary). Suomen Lääkärilehti (Finn Med J)., 61, pp. 4689-4694.
24. Ghosh, S. and Aronow, WS. (2003) Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program to treat dyslipidemia. J Gerontol: Med Sci., 58, pp. M432-M435.